Cenova
VC Fund
Shanghai, China
Cenova is a VC fund in Shanghai focused on Medical and Health Care. Cenova Capital is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU and is one of the earliest investors in private healthcare services and digital health, with helps to facilitate the transformation of healthcare in China from an exclusively state-owned system to a more efficient, market-oriented system. CenovaCapital is healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sector in China. Since inception in 2010, Cenova now has five funds under management with investments in over 50 companies in healthcare services, pharmaceuticals, medical devices and digital heath. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.
- Total investments:
- 60
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Cenova invests in
Stages Cenova invests in
Countries Cenova invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Round size
- Series A
- $2.9M–$45M
- Series B
- $13M–$61M
- Series C
- $15M–$100M
Investment Focus
Industry
- Medical 23 (38%)
- Health Care 23 (38%)
- Biotechnology 13 (22%)
- Medical Device 8 (13%)
- Pharmaceutical 8 (13%)
Stage
- Series B 19 (32%)
- Series A 18 (30%)
- Series C 8 (13%)
- Series D 4 (7%)
- Seed 3 (5%)
Country
- China 43 (72%)
- United States 3 (5%)
- Hong Kong 1 (2%)
- Singapore 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jun Wu
Founder and Chairman
|
Founder and Chairman | Total investments: 6 | Find email | |
Kai Zhao
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Lehman Gu
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Leo Li
Vice President
|
Vice President | Total investments: 0 | Find email | |
Melissa Zhang
Vice President
|
Vice President | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Simnova Biotherapeutics is a biopharmaceutical company that focuses on the research and development of cell therapies for cancer treatment. The company's primary therapeutic focus is CAR-based cell therapy for patients with either hematologic malignancies or solid tumors. Simnova Biotherapeutics is known for its innovative approach todeveloping patient-centered therapeutics using current science and technology. The company's lead product is SNC102, a cell therapy product that has been approved for clinical trials. Simnova Biotherapeutics is committed to creating a healthy, inclusive, and harmonious working environment. | $59.3M / Series B / Aug 18, 2026 | ||
|
Deep Cell
|
Deep Cell is a Chinese AI driven drug discovery and virtual cell modeling startup. The company integrates artificial intelligence with multi scale molecular physics to construct explainable virtual cell world models, aiming to revolutionize paradigm shifting drug designs and simulate cellular responses to complex diseases. | $14.8M / Seed / Aug 10, 2026 | |
| Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. | $50M / Series C / May 18, 2026 | ||
|
Ruize Health
|
Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance. | Series A / Mar 05, 2026 | |
| Aires is a high-tech enterprise specializing in the research, development, manufacturing, and sales of contact lenses, dedicated to delivering high-quality vision care products through advanced lens technology, strict quality standards, and innovative designs that ensure comfort, safety, and clear vision for consumers. | $14.5M / Series C / Mar 02, 2026 | ||
| BRC Biotechnology specializes in quality testing services for biopharmaceutical compliance. BRC Biotechnology supports biological agents, quality evaluation of biopharmaceutical goods such as cell gene therapy, nucleic acid medications, and vaccines. | $14.3M / Series A / Dec 29, 2025 | ||
| Shanghai Aipuqiang Particle Equipment is committed to providing customers with independently developed advanced proton therapy systems, based on independent innovation and with the mission of creating domestically produced high-end particle therapy technology to benefit cancer patients and contribute to the Healthy China strategy. | $142.7M / Series B / Dec 27, 2025 | ||
Fine Vision
|
Fine Vision is a company with R&D facilities in Nanjing and Wuhan that focuses on femtosecond laser application research in the fields of ocular surgery and biomaterial processing. The entire femtosecond laser corneal refractive surgery equipment, its first commercially available item, was developed by the university's WuhanOptoelectronics National Research Center under the Huazhong Technology Technology transition. | Series A / Nov 19, 2025 | |
| Agile Medical, a surgical robot company, focuses on research, development, and industrialization of intelligent surgical products. Agile Medical's technology innovation platform covers mechanics, electronics, optics, computing, and software. | Series B / Nov 03, 2025 | ||
|
Sieran Medical
|
Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology. | $14M / Venture - Series Unknown / Sep 02, 2025 | |
| See all 60 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Cenova invest in?
Cenova invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series A stage. Most of the 60 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Cenova's check size?
Cenova typically joins rounds of $2.9M–$45M at Series A, $13M–$61M at Series B and $15M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cenova participates in.
How do I contact Cenova?
Public channels for Cenova include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cenova?
The team at Cenova includes Jun Wu (Founder and Chairman), Kai Zhao (Managing Partner) and Lehman Gu (Venture Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
